Published in Lancet Oncol on September 13, 2005
Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy. J Clin Oncol (2012) 3.03
Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer (2010) 1.45
Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer (2009) 1.28
Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer (2011) 1.19
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer (2013) 1.12
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial†. Ann Oncol (2015) 0.91
Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother (2013) 0.90
How do patient expectancies, quality of life, and postchemotherapy nausea interrelate? Cancer (2008) 0.89
Distress before chemotherapy predicts delayed but not acute nausea. Support Care Cancer (2006) 0.87
Defining optimal control of chemotherapy-induced nausea and vomiting-based on patients' experience. Support Care Cancer (2015) 0.87
Chemotherapy-and cancer-related nausea and vomiting. Curr Oncol (2008) 0.86
Acupressure bands are effective in reducing radiation therapy-related nausea. J Pain Symptom Manage (2009) 0.84
Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea? Oncologist (2015) 0.83
Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy. Cancer Manag Res (2014) 0.81
Treatment of Nausea and Vomiting During Chemotherapy. US Oncol Hematol (2011) 0.80
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea. Int J Clin Oncol (2016) 0.80
Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis. Am Health Drug Benefits (2014) 0.79
Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients. Ecancermedicalscience (2015) 0.78
A Randomized, Double-Blind Pilot Study of Dose Comparison of Ramosetron to Prevent Chemotherapy-Induced Nausea and Vomiting. Biomed Res Int (2015) 0.78
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy. Cancer Manag Res (2009) 0.78
Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation. Support Care Cancer (2013) 0.78
Chemotherapy-Induced Nausea and Vomiting. US Oncol (2008) 0.76
Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison. Oncotarget (2016) 0.75
Pattern of chemotherapy-related adverse effects among adult cancer patients treated at Gondar University Referral Hospital, Ethiopia: a cross-sectional study. Drug Healthc Patient Saf (2016) 0.75
Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists. Support Care Cancer (2017) 0.75
Palonosetron versus older 5-HT3 receptor antagonists for nausea prevention in patients receiving chemotherapy: a multistudy analysis. J Community Support Oncol (2014) 0.75
Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. Support Care Cancer (2016) 0.75
Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30. Eur J Nucl Med Mol Imaging (2017) 0.75
Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer (2004) 3.04
Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol (1999) 2.97
Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol (1997) 2.96
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol (2005) 2.86
Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. The Italian Group for Antiemetic Research. N Engl J Med (2000) 2.70
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol (2005) 2.00
ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery. Am J Health Syst Pharm (1999) 1.83
Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med (1993) 1.52
Etiology and treatment of the psychological side effects associated with cancer chemotherapy: a critical review and discussion. Psychol Bull (1988) 1.19
Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer (2004) 1.13
Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer (2004) 1.06
Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1998) 1.05
Conditioned side effects induced by cancer chemotherapy: prevention through behavioral treatment. J Consult Clin Psychol (1987) 1.04
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol (1997) 0.98
Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother (2003) 0.91
Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:. J Clin Oncol (2004) 0.85
A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol (2003) 0.81
A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis. Cancer (1998) 0.79
Prophylaxis of delayed nausea and vomiting after cancer chemotherapy. Neth J Med (1995) 0.79
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol (2006) 7.14
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol (2010) 6.34
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol (2008) 6.31
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol (2006) 4.97
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol (2008) 4.79
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med (2015) 4.53
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol (2005) 3.88
Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med (2012) 3.86
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol (2005) 3.50
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol (2005) 3.41
Genomic analyses identify distinct patterns of selection in domesticated pigs and Tibetan wild boars. Nat Genet (2013) 3.41
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol (2006) 3.20
Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol (2013) 3.18
Cancer-related fatigue: the scale of the problem. Oncologist (2007) 3.03
Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy. J Clin Oncol (2012) 3.03
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol (2011) 3.02
Fungal small RNAs suppress plant immunity by hijacking host RNA interference pathways. Science (2013) 2.99
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol (2009) 2.73
An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol (2004) 2.45
Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet (2005) 2.39
Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol (2010) 2.28
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol (2009) 2.27
Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. J Clin Oncol (2008) 2.26
Mechanisms of cancer-related fatigue. Oncologist (2007) 2.25
Factors motivating and affecting health information exchange usage. J Am Med Inform Assoc (2011) 2.17
The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion (2007) 2.12
Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol (2002) 2.09
Arabidopsis Argonaute 2 regulates innate immunity via miRNA393(∗)-mediated silencing of a Golgi-localized SNARE gene, MEMB12. Mol Cell (2011) 2.01
Community-based clinical oncology research trials for cancer-related fatigue. J Support Oncol (2006) 2.01
Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin Oncol (2007) 1.98
Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2006) 1.83
Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol (2009) 1.80
Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer (2005) 1.76
Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. J Clin Oncol (2009) 1.73
Health-related quality of life consequences of implantable cardioverter defibrillators: results from MADIT II. Med Care (2007) 1.70
The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol (2006) 1.70
Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma. J Clin Oncol (2002) 1.65
Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol (2011) 1.65
Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol (2003) 1.63
Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol (2010) 1.61
The prevalence of weight concerns in a smoking abstinence clinical trial. Addict Behav (2005) 1.60
Association of a cancer diagnosis with vulnerability and frailty in older Medicare beneficiaries. J Natl Cancer Inst (2009) 1.56
Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Support Care Cancer (2001) 1.52
Avoiding and resolving conflicts between DNA replication and transcription. DNA Repair (Amst) (2007) 1.51
Cost-effectiveness of cardiac resynchronization therapy in the MADIT-CRT trial. J Cardiovasc Electrophysiol (2012) 1.50
Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst (2013) 1.47
Cancer-related fatigue and sleep disorders. Oncologist (2007) 1.47
Multicenter, randomized controlled trial of yoga for sleep quality among cancer survivors. J Clin Oncol (2013) 1.46
Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol (2008) 1.41
A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer (2003) 1.41
Traumatic stress symptoms among women with recently diagnosed primary breast cancer. J Trauma Stress (2002) 1.40
Acustimulation wristbands for the relief of chemotherapy-induced nausea. Altern Ther Health Med (2002) 1.39
Fatigue associated with cancer and its treatment. Support Care Cancer (2001) 1.38
Occurrence, severity, and longitudinal course of twelve common symptoms in 1129 consecutive patients during radiotherapy for cancer. J Pain Symptom Manage (2005) 1.37
RecN protein and transcription factor DksA combine to promote faithful recombinational repair of DNA double-strand breaks. Mol Microbiol (2005) 1.37
Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue. Oncologist (2007) 1.36
Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Lung Cancer (2007) 1.36
An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol (2011) 1.32
Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. J Clin Oncol (2005) 1.32
Assessment of cancer-related fatigue: implications for clinical diagnosis and treatment. Oncologist (2007) 1.32
Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry (2014) 1.30
Hypoxia-responsive miRNAs target argonaute 1 to promote angiogenesis. J Clin Invest (2013) 1.30
Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. Cancer (2005) 1.28
Tai Chi Chuan, health-related quality of life and self-esteem: a randomized trial with breast cancer survivors. Support Care Cancer (2004) 1.28
Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer (2009) 1.28
Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol (2004) 1.28
Management of cancer-related fatigue. Cancer Invest (2005) 1.26
Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol (2009) 1.24
Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat (2005) 1.24
The 73 kD subunit of the cleavage and polyadenylation specificity factor (CPSF) complex affects reproductive development in Arabidopsis. Plant Mol Biol (2006) 1.23
Perceived discrimination, psychological distress, and current smoking status: results from the Behavioral Risk Factor Surveillance System Reactions to Race module, 2004-2008. Am J Public Health (2012) 1.23
A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1). Cancer (2010) 1.22
Arabidopsis mRNA polyadenylation machinery: comprehensive analysis of protein-protein interactions and gene expression profiling. BMC Genomics (2008) 1.20
Ground tit genome reveals avian adaptation to living at high altitudes in the Tibetan plateau. Nat Commun (2013) 1.20
Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc (2006) 1.20
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol (2009) 1.20